NCT06784076View on ClinicalTrials.gov

Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue

Not yet recruitingOBSERVATIONAL

Enrollment

20

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

March 17, 2025

Study Completion Date

March 15, 2027

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Anifrolumab

Anifrolumab 300mg intravenous infusions administered as described in the EU SmPC

All Listed Sponsors

lead

NHS Greater Glasgow and Clyde

OTHER